Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Metastatic Urothelial Carcinoma Clinical Trial

Official title:
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation

Status Active, not recruiting

Clinical Trial Summary

This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and/or TSC2 mutations (changes in deoxyribonucleic acid [DNA]). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the overall response rate (ORR) defined as complete response (CR) and partial response (PR) in patients with locally advanced or metastatic transitional cell carcinoma (TCC) harboring a TSC1 mutation. SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of sapanisertib (MLN0128) (TAK-228) in patients with locally advanced or metastatic TCC harboring a TSC1 or TSC2 mutation. II. To evaluate progression free survival (PFS) and overall survival (OS). EXPLORATORY OBJECTIVES: I. To determine the ORR in patients with locally advanced or metastatic TCC harboring a TSC2 mutation. II. To evaluate toxicity, PFS, and OS in TSC2 mutation patients. OUTLINE: Patients receive sapanisertib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks and every 6 months thereafter. ;

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Transitional Cell
Locally Advanced Bladder Urothelial Carcinoma
Metastatic Transitional Cell Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Bladder Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT03047213
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 24, 2017
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05700344` - SOGUG-AVELUMAB_RWD
Recruiting	`NCT04623502` - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	N/A
Recruiting	`NCT05107674` - A Study of NX-1607 in Adults With Advanced Malignancies	Phase 1
Recruiting	`NCT04953104` - Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	Phase 2
Withdrawn	`NCT06050954` - A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)	Phase 2
Active, not recruiting	`NCT03534804` - Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT00365157` - Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction	Phase 1/Phase 2
Withdrawn	`NCT06018116` - A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.	Phase 2
Recruiting	`NCT05544552` - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations	Phase 1/Phase 2
Recruiting	`NCT04936230` - Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer	Phase 2
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Terminated	`NCT05052372` - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Terminated	`NCT03115801` - A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers	Phase 2
Active, not recruiting	`NCT03854474` - Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma	Phase 1/Phase 2
Terminated	`NCT02693717` - Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer	Phase 2
Recruiting	`NCT04848519` - Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT04724018` - Sacituzumab Govitecan Plus EV in Metastatic UC	Phase 1
Terminated	`NCT04003610` - Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)	Phase 2
Recruiting	`NCT04383067` - A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients	Phase 2
Not yet recruiting	`NCT03108261` - Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	Phase 2